Browse TK2

Summary
SymbolTK2
Namethymidine kinase 2, mitochondrial
Aliases MTDPS2
Chromosomal Location16q22-q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion.
Domain PF01712 Deoxynucleoside kinase
Function

Phosphorylates thymidine, deoxycytidine, and deoxyuridine in the mitochondrial matrix. In non-replicating cells, where cytosolic dNTP synthesis is down-regulated, mtDNA synthesis depends solely on TK2 and DGUOK. Widely used as target of antiviral and chemotherapeutic agents.

> Gene Ontology
 
Biological Process GO:0006213 pyrimidine nucleoside metabolic process
GO:0008655 pyrimidine-containing compound salvage
GO:0009116 nucleoside metabolic process
GO:0009120 deoxyribonucleoside metabolic process
GO:0009123 nucleoside monophosphate metabolic process
GO:0009124 nucleoside monophosphate biosynthetic process
GO:0009157 deoxyribonucleoside monophosphate biosynthetic process
GO:0009162 deoxyribonucleoside monophosphate metabolic process
GO:0009163 nucleoside biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0043094 cellular metabolic compound salvage
GO:0043097 pyrimidine nucleoside salvage
GO:0043174 nucleoside salvage
GO:0046092 deoxycytidine metabolic process
GO:0046104 thymidine metabolic process
GO:0046125 pyrimidine deoxyribonucleoside metabolic process
GO:0046134 pyrimidine nucleoside biosynthetic process
GO:0071897 DNA biosynthetic process
GO:0072527 pyrimidine-containing compound metabolic process
GO:0072528 pyrimidine-containing compound biosynthetic process
GO:1901293 nucleoside phosphate biosynthetic process
GO:1901657 glycosyl compound metabolic process
GO:1901659 glycosyl compound biosynthetic process
Molecular Function GO:0004137 deoxycytidine kinase activity
GO:0004797 thymidine kinase activity
GO:0019136 deoxynucleoside kinase activity
GO:0019205 nucleobase-containing compound kinase activity
GO:0019206 nucleoside kinase activity
Cellular Component GO:0005759 mitochondrial matrix
> KEGG and Reactome Pathway
 
KEGG hsa00240 Pyrimidine metabolism
hsa00983 Drug metabolism - other enzymes
hsa01100 Metabolic pathways
Reactome R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-113510: E2F mediated regulation of DNA replication
R-HSA-69206: G1/S Transition
R-HSA-69205: G1/S-Specific Transcription
R-HSA-1430728: Metabolism
R-HSA-15869: Metabolism of nucleotides
R-HSA-453279: Mitotic G1-G1/S phases
R-HSA-73848: Pyrimidine metabolism
R-HSA-73614: Pyrimidine salvage reactions
Summary
SymbolTK2
Namethymidine kinase 2, mitochondrial
Aliases MTDPS2
Chromosomal Location16q22-q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TK2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTK2
Namethymidine kinase 2, mitochondrial
Aliases MTDPS2
Chromosomal Location16q22-q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TK2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.73; FDR: 0.04630 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolTK2
Namethymidine kinase 2, mitochondrial
Aliases MTDPS2
Chromosomal Location16q22-q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TK2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3080.206
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.730.631
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0070.995
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1030.698
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3510.83
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2070.924
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2890.41
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1950.894
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.4050.804
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4820.732
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.050.617
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1940.011
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TK2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTK2
Namethymidine kinase 2, mitochondrial
Aliases MTDPS2
Chromosomal Location16q22-q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TK2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTK2
Namethymidine kinase 2, mitochondrial
Aliases MTDPS2
Chromosomal Location16q22-q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TK2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TK2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTK2
Namethymidine kinase 2, mitochondrial
Aliases MTDPS2
Chromosomal Location16q22-q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TK2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTK2
Namethymidine kinase 2, mitochondrial
Aliases MTDPS2
Chromosomal Location16q22-q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TK2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTK2
Namethymidine kinase 2, mitochondrial
Aliases MTDPS2
Chromosomal Location16q22-q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TK2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTK2
Namethymidine kinase 2, mitochondrial
Aliases MTDPS2
Chromosomal Location16q22-q23.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TK2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting TK2.
ID Name Drug Type Targets #Targets
DB02452Thymidine-5'-TriphosphateSmall MoleculeTK1, TK22
DB025942'-DeoxycytidineSmall MoleculeDCK, TK22
DB04485DeoxythymidineSmall MoleculeTK21